---
title: "Here's How Much $100 Invested In BeOne Medicines 10 Years Ago Would Be Worth Today"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286947117.md"
description: "BeOne Medicines (NASDAQ:ONC) has achieved an annualized return of 26.69% over the past decade, outperforming the market by 13.23%. A $100 investment in ONC 10 years ago would now be worth $1,057.17, reflecting the significant impact of compounded returns. The company's current market capitalization stands at $29.88 billion."
datetime: "2026-05-19T16:45:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286947117.md)
  - [en](https://longbridge.com/en/news/286947117.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286947117.md)
---

# Here's How Much $100 Invested In BeOne Medicines 10 Years Ago Would Be Worth Today

BeOne Medicines (NASDAQ:ONC) has outperformed the market over the past 10 years by 13.23% on an annualized basis producing an average annual return of 26.69%. Currently, BeOne Medicines has a market capitalization of $29.88 billion.

**Buying $100 In ONC:** If an investor had bought $100 of ONC stock 10 years ago, it would be worth **$1,057.17** today based on a price of $288.00 for ONC at the time of writing.

### BeOne Medicines's Performance Over Last 10 Years

![comp_fig](https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1779209136_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg)

Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.

_This article was generated by Benzinga's automated content engine and reviewed by an editor._

### Related Stocks

- [ONC.US](https://longbridge.com/en/quote/ONC.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

- [BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma | ONC Stock News](https://longbridge.com/en/news/286297796.md)
- [<![CDATA[Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates]]>](https://longbridge.com/en/news/286787081.md)
- [BeOne Wins First-in-Class U.S. FDA Nod for BCL2 Drug in Relapsed Mantle Cell Lymphoma](https://longbridge.com/en/news/286330888.md)
- [<![CDATA[Pharmaceutical Executive Daily: FDA Approves Beqalzi and Inqovi]]>](https://longbridge.com/en/news/286458336.md)
- [US FDA approves BeOne's drug for a type of blood cancer](https://longbridge.com/en/news/286298271.md)